Key Highlights
- Hims & Hers shares gained 7% following the announcement of an enhanced collaboration with Eli Lilly
- Platform providers can now offer Zepbound vials, KwikPen, and Foundayo prescriptions through LillyDirect fulfillment
- This partnership arrives weeks after a comparable arrangement with Novo Nordisk for Wegovy distribution
- Leerink Partners analyst Michael Cherny raised concerns about Hims’ value proposition as a patient access portal
- CEO Andrew Dudum drew parallels between Hims and early-stage Netflix to defend the strategic direction
Hims & Hers Health (HIMS) shares jumped 7% Thursday following the company’s announcement of broader access to Eli Lilly weight loss treatments through its telehealth platform.
Hims & Hers Health, Inc., HIMS
Healthcare providers using the Hims platform now have the capability to route prescriptions for Zepbound vials, KwikPen devices, and Foundayo directly to LillyDirect’s pharmacy network. Patients gain access to self-pay options while connecting with licensed medical professionals who can recommend FDA-cleared GLP-1 treatments.
The expanded arrangement positions Hims to offer what the company describes as comprehensive FDA-approved GLP-1 options on its digital health platform. Services include clinical oversight and nutritional counseling delivered through a subscription framework.
This marks the second significant GLP-1 collaboration within two months. March brought a settlement with Novo Nordisk, where the pharmaceutical giant withdrew patent litigation while Hims agreed to distribute branded Ozempic and Wegovy through its channels.
The Novo settlement required specific commitments from Hims. The company agreed to reduce its large-scale compounding operations for GLP-1 medications as part of the resolution. The Eli Lilly arrangement follows a similar framework.
Hims had established a substantial presence during the 2024 GLP-1 shortage period, when surging demand combined with constrained availability from pharmaceutical manufacturers created opportunities for the telehealth company. With supply chains now stabilized, market conditions have evolved.
Analyst Questions Platform Value Proposition
Leerink Partners analyst Michael Cherny provided a nuanced perspective on the development. He recognized that Hims is broadening its service offerings and “serving as an intermediary to create more options” for individuals seeking treatment.
Cherny simultaneously expressed uncertainty about Hims’ strategic positioning, noting the challenge of determining “what role Hims is playing here beyond being the front door to patients accessing Lilly products.” This concern gains relevance as the company transitions away from compounding operations.
CEO Draws Netflix Parallel
CEO Andrew Dudum rejected characterizations of these partnerships as strategic setbacks. His statement drew comparisons to Netflix during its formative period.
“Netflix wasn’t just renting DVDs,” Dudum stated. “It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most.”
The company highlighted its weight loss membership program as validation of a more comprehensive service model. Subscribers receive round-the-clock care team availability, customized nutrition strategies, continuous clinical monitoring, and community engagement through the Hims & Hers Weight Loss network.
Hims stated its objective centers on aligning users with appropriate treatment pathways tailored to their specific medical backgrounds, personal preferences, and wellness objectives.
Market participants responded favorably to the CEO’s strategic narrative. HIMS shares maintained a 0.4% gain later in trading while the S&P 500 showed modest declines. Eli Lilly shares remained unchanged for the session.
The Eli Lilly collaboration represents another step in Hims’ strategic evolution within the GLP-1 marketplace, shifting from a provider of compounded alternatives toward a distribution platform facilitating patient access to branded therapies.
